GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

clinical trial

Details

Instance of: clinical trial
Start time: September 2011
End time: January 2013
Country: Germany, United States
Main subject: combination therapy, ledipasvir, hepatitis, hepatitis C, hepatitis A
clinical trial phase: phase II clinical trial
minimum age: 18
number of participants: 170
research site: University of Arizona, University of California, San Diego, Kaiser Permanente, California Pacific Medical Center, Whitman-Walker Health, Avail Clinical Research, University of Kansas Medical Center, Mercy Medical Center, Johns Hopkins University, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Henry Ford Health
study type: interventional study
title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in Treatment-Experienced Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Nothing in the MetaHistoryBook collection references this item yet.